News & Updates

Show Multimedia Only

Artificial liver device improves outcomes, but with safety concerns

30 Sep 2022 by

The Molecular Adsorbent Recirculating System (MARS), a nonbiological artificial liver device, leads to better clinical and biological outcomes among patients receiving the intervention, according to a recent study. However, adverse events and safety concerns related to the device are common.

Artificial liver device improves outcomes, but with safety concerns

30 Sep 2022

Low-dose IL-2 falls short of inducing transplant tolerance

26 Sep 2022

While treatment with low-dose interleukin (IL)-2 leads to the expansion of circulating regulatory T cells (Treg), it does not appear to induce allograft tolerance among liver transplant patients, reports a new study.

Low-dose IL-2 falls short of inducing transplant tolerance

26 Sep 2022

Intensive weight-loss does not improve outcomes in obese NAFLD patients

22 Sep 2022

An intensive weight-loss intervention has failed to substantially improve the treatment outcomes among obese patients with nonalcoholic fatty liver disease (NAFLD), reports a recent study.

Intensive weight-loss does not improve outcomes in obese NAFLD patients

22 Sep 2022

Vebicorvir plus Nrtl safe, well tolerated in patients with chronic HBV infection

16 Sep 2022 by

Treatment with vebicorvir (VBR) plus nucleos(t)ide reverse transcriptase inhibitors (NrtIs) among virologically suppressed patients with chronic hepatitis B virus (HBV) is well tolerated and has a favourable safety profile, according to a 24-week study.

Vebicorvir plus Nrtl safe, well tolerated in patients with chronic HBV infection

16 Sep 2022

Is albumin superior to plasmalyte in cirrhosis, sepsis-induced hypotension?

13 Sep 2022

Use of 20% albumin in patients with cirrhosis and sepsis-induced hypotension results in faster improvement in haemodynamics and lactate clearance than plasmalyte, but 28-day survival is similar, according to a study.

Is albumin superior to plasmalyte in cirrhosis, sepsis-induced hypotension?

13 Sep 2022

Semaglutide plus cilofexor, firsocostat well tolerated in NASH-related fibrosis

13 Sep 2022

Treatment with semaglutide with firsocostat and/or cilofexor is well tolerated in patients with mild-to-moderate fibrosis due to nonalcoholic steatohepatitis (NASH), a study has shown.

Semaglutide plus cilofexor, firsocostat well tolerated in NASH-related fibrosis

13 Sep 2022

STRIDE regimen benefit in unresectable HCC consistent across baseline liver function

11 Sep 2022 by

The overall survival (OS) benefit observed with the STRIDE regimen compared with sorafenib in patients with unresectable hepatocellular carcinoma (HCC) is consistent regardless of baseline liver function, according to exploratory analysis of data from the phase III HIMALAYA trial presented at ESMO GI 2022.

STRIDE regimen benefit in unresectable HCC consistent across baseline liver function

11 Sep 2022

Inflammatory diet ups NAFLD risk, especially in men

30 Aug 2022

A dietary pattern with high inflammatory potential appears to increase the risk of nonalcoholic fatty liver disease (NAFLD), reports a study, adding that this association is greater in men.

Inflammatory diet ups NAFLD risk, especially in men

30 Aug 2022

Statin improves survival in liver transplant recipients

28 Aug 2022

Recipients of liver transplantation fare well with the use of statins, which a recent study showing that the drugs confer survival advantage.

Statin improves survival in liver transplant recipients

28 Aug 2022

Durvalumab + gemcitabine-cisplatin benefit in biliary tract cancer consistent across tumour locations

27 Aug 2022 by

The benefit of adding durvalumab to gemcitabine plus cisplatin chemotherapy in patients with advanced biliary tract cancer (BTC) was consistent regardless of primary tumour location, according to a subgroup analysis of the phase III TOPAZ-1 study presented at ESMO GI 2022.

Durvalumab + gemcitabine-cisplatin benefit in biliary tract cancer consistent across tumour locations

27 Aug 2022

News & Updates

Showing Hepatology articles

Showing

Specialty:

Artificial liver device improves outcomes, but with safety concerns

Artificial liver device improves outcomes, but with safety concerns

Low-dose IL-2 falls short of inducing transplant tolerance

Low-dose IL-2 falls short of inducing transplant tolerance

Intensive weight-loss does not improve outcomes in obese NAFLD patients

Intensive weight-loss does not improve outcomes in obese NAFLD patients

Vebicorvir plus Nrtl safe, well tolerated in patients with chronic HBV infection

Vebicorvir plus Nrtl safe, well tolerated in patients with chronic HBV infection

Is albumin superior to plasmalyte in cirrhosis, sepsis-induced hypotension?

Is albumin superior to plasmalyte in cirrhosis, sepsis-induced hypotension?

Semaglutide plus cilofexor, firsocostat well tolerated in NASH-related fibrosis

Semaglutide plus cilofexor, firsocostat well tolerated in NASH-related fibrosis

STRIDE regimen benefit in unresectable HCC consistent across baseline liver function

STRIDE regimen benefit in unresectable HCC consistent across baseline liver function

Inflammatory diet ups NAFLD risk, especially in men

Inflammatory diet ups NAFLD risk, especially in men

Statin improves survival in liver transplant recipients

Statin improves survival in liver transplant recipients

Durvalumab + gemcitabine-cisplatin benefit in biliary tract cancer consistent across tumour locations

Durvalumab + gemcitabine-cisplatin benefit in biliary tract cancer consistent across tumour locations